Recurrent breast cancer is typically an incurable disease. Consequently, the tendency of breast cancers to recur following treatment is the most important determinant of clinical outcome. Recurrent tumors invariably arise from the reservoir of residual tumor cells (RTCs) that can persist in patients in a presumed dormant state for many years after treatment of their primary tumor. As such, minimal residual disease, tumor dormancy, and recurrence constitute fundamental manifestations of tumor progression that collectively are responsible for the vast majority of breast cancer deaths. Despite the unrivaled clinical importance of these aspects of breast cancer progression, however, the mechanisms underlying them are largely unknown. Consequently, understanding the biology of RTCs and elucidating the molecular pathways that contribute to tumor dormancy and recurrence is a critical priority in cancer research. We propose that disabling the survival mechanisms by which dormant RTCs persist in breast cancer patients following treatment will deplete this critical reservoir of cells, reduce tumor recurrence, and thereby improve survival. Using genetically engineered mouse models that faithfully recapitulate tumor dormancy and recurrence, we have determined that uPAR and its binding partner, ?5 integrin, are markedly down-regulated in dormant RTCs, but are subsequently up-regulated, along with FAK activity, in spontaneous recurrent tumors that arise with a stochastic latency period. When taken together with the observations that elevated uPAR and ?5 integrin expression are each strongly associated with an increased risk of recurrence in women with breast cancer, we hypothesize that down-regulation of uPAR and ?5?1 integrin are required for entrance into the dormant state following therapy, and that subsequent up-regulation of uPAR/?5?1/FAK signaling promotes mammary tumor recurrence by inducing the re-entry of dormant RTCs into the cell cycle.
The specific aims of this proposal are to: (1) Define uPAR/?5?1/FAK pathway status in residual disease in mice and in patients. uPAR/?5?1/FAK pathway activation will be evaluated in primary tumors, recurrent tumors, RTC in the mammary gland, and DTC in the BM and lungs in GEM models following targeted therapy or chemotherapy. Companion studies will evaluate the uPAR/?5?1/FAK pathway in BM DTCs, as well as primary and recurrent metastatic tumor cells in breast cancer patients; and (2) Determine the impact of uPAR/?5?1/ FAK pathway modulation on residual disease and recurrence. By probing the biology of RTCs and the pathways that contribute to tumor recurrence, the proposed studies will advance the therapeutic goals of maintaining tumor cells in a dormant state, inducing their death by targeting their survival mechanisms, or blocking preferred pathways of recurrence. We anticipate that this knowledge will facilitate the development of more effective therapeutic approaches to recurrence that could improve the treatment options available to millions of breast cancer survivors.
Residual breast cancer cells that survive therapy have the ability to survive in a dormant state following treatment and linger unrecognized for more than a decade before emerging as recurrent disease. Since recurrent breast cancer is typically an incurable disease, and since recurrent breast cancers typically arise from disseminated tumor cells, understanding the biology of minimal residual disease and elucidating the molecular pathways that contribute to tumor dormancy and recurrence is a critical priority in breast cancer research. This application is focused on that goal.
|Feng, Yi; Pan, Tien-Chi; Pant, Dhruv K et al. (2014) SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling. Cancer Discov 4:790-803|
|Alvarez, James V; Belka, George K; Pan, Tien-Chi et al. (2014) Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. Cancer Res 74:7583-98|
|Payne, Ania W; Pant, Dhruv K; Pan, Tien-Chi et al. (2014) Ceramide kinase promotes tumor cell survival and mammary tumor recurrence. Cancer Res 74:6352-63|
|Magnitsky, S; Belka, G K; Sterner, C et al. (2013) Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models. NMR Biomed 26:35-42|
|Alvarez, James V; Pan, Tien-Chi; Ruth, Jason et al. (2013) Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. Cancer Cell 24:30-44|